Jiangxi Sanxin Medtec Co.Ltd(300453) 2021 annual report summary
Securities code: Jiangxi Sanxin Medtec Co.Ltd(300453) securities abbreviation: Jiangxi Sanxin Medtec Co.Ltd(300453) Announcement No.: 2022012 Jiangxi Sanxin Medtec Co.Ltd(300453) 2021 annual report summary I. important tips the summary of this annual report is from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, Investors shall carefully read the full text of the annual report in the media designated by the CSRC. All directors attended the board meeting to consider this annual report. The audit opinion of Daxin Certified Public Accountants (special general partnership) on the company’s financial report this year is: standard unqualified opinion. The change of accounting firm during the reporting period is not applicable to the prompt of non-standard audit opinion □ applicable √ not applicable to the company’s non-profit at the time of listing and no profit at present □ applicable √ not applicable to the profit distribution plan of common stock or the plan of converting accumulation fund into share capital in the reporting period considered by the board of directors √ applicable □ not applicable
The company’s profit distribution plan for ordinary shares reviewed and approved by the board of directors is: take 39402750000 shares as the base, distribute cash dividend of 1.50 yuan (including tax) to all shareholders for every 10 shares, give bonus shares of 0 shares (including tax), and transfer capital reserve to all shareholders for every 10 shares.
Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable □ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Jiangxi Sanxin Medtec Co.Ltd(300453) stock code Jiangxi Sanxin Medtec Co.Ltd(300453)
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Liu Ming, Zhou Wenyan
Office address: No. 999, Fushan Avenue, Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province
Fax: 079185950380
Tel: 079185950380
E-mail sanxinkeji1997163.com. sanxinkeji1997163.com.
2. Introduction to main business or products during the reporting period
The company always adheres to the enterprise development strategy of building a blood purification industry platform operator and a first-class manufacturer in the field of medical consumables. From rooted medical treatment to focused medical treatment, from ingenuity medical treatment to dream medical treatment, Jiangxi Sanxin Medtec Co.Ltd(300453) with a global vision, closely following the national development strategy, close to clinical needs, relying on the perfect quality management system and mature R & D and manufacturing advantages, has taken the lead in passing the CE, CMD quality management system and product certification and the listing license of fda510 (k) in the United States. Strive for innovation and excellence,
Jiangxi Sanxin Medtec Co.Ltd(300453) 2021 annual report summary
Jiangxi Sanxin Medtec Co.Ltd(300453) is committed to providing patients with safe and high-quality products and services, and adhering to the corporate responsibility and mission for medical and health undertakings.
(I) main business of the company
During the reporting period, the company’s business mainly involved six series products of “blood purification”, “injection”, “indwelling catheter”, “infusion and blood transfusion”, “cardiothoracic surgery” and “protection” Jiangxi Sanxin Medtec Co.Ltd(300453) always adheres to the original intention of “caring for health and focusing on safe medical treatment”, takes promoting the development of medical and health undertakings as its mission, and is committed to providing excellent medical products and services to benefit the world by continuously improving the industrial layout and continuously developing new products.
(II) main business analysis
During the reporting period, the company focused on its main business, actively carried out various work closely around the company’s development strategy and the annual work plan formulated by the board of directors, and achieved an operating revenue of 116428800 yuan, an increase of 23.81% over the same period of last year; The net profit attributable to the shareholders of the listed company was 1559107 million yuan, an increase of 34.84% over the same period last year. During the reporting period, the company’s business was mainly reflected in the following areas:
Blood purification: during the reporting period, the sales revenue of blood purification products was 7356805 million yuan, an increase of 26.16% over the same period of last year. The sales revenue of such products accounted for 63.19% of the total revenue of the company.
Injection: during the reporting period, the sales revenue of injection products was 195956100 yuan, an increase of 160.03% over the same period of the previous year. The sales revenue of such products accounted for 16.83% of the total revenue of the company. Among them, the sales volume of vaccine syringes was 376 million, an increase of 321% over the same period of the previous year. During the reporting period, as a manufacturer of vaccine syringes, the company was not only the main supplier of covid-19 syringes for vaccination in China, but also an important supplier of United Nations vaccine syringes, making important contributions to global vaccination.
Indwelling catheter: during the reporting period, the sales revenue of indwelling catheter products was 72.836 million yuan, an increase of 2.31% over the same period of last year, and the sales revenue of such products accounted for 6.26% of the total revenue of the company.
Infusion and blood transfusion: during the reporting period, the sales revenue of infusion and blood transfusion products was 70.37 million yuan, an increase of 8.81% over the same period of last year, and the sales revenue of such products accounted for 6.04% of the total revenue of the company.
Cardiothoracic surgery: during the reporting period, the sales revenue of cardiothoracic surgery products was 692849 million yuan, an increase of 20.66% over the same period of last year. The sales revenue of such products accounted for 5.95% of the total revenue of the company.
Protection: during the reporting period, the sales revenue of protection products was 1.5288 million yuan, a decrease of 98.02% over the same period of last year, and the sales revenue of such products accounted for 0.13% of the total revenue of the company.
Protection is a new business of the company in response to the government’s call for emergency after the outbreak in 2020. With the effective control of the epidemic in China and the rapid increase of the production capacity of similar products outside China, the market demand for protection products continues to decline, and the sales volume of such products of the company has decreased significantly. 3. Main accounting data and financial indicators (1) whether the company needs to retroactively adjust or restate the accounting data of previous years in recent three years □ yes √ no
Unit: Yuan
Year end 2021 year end 2020 year end increase or decrease over the previous year year end 2019 year end
Total assets 140603952212124475430725 12.96% 114570035746
Net assets attributable to shareholders of listed companies 9055063891878519839169 15.32% 66915140074
20212020 year-on-year increase or decrease 2019
Operating income 11642887635794038558906 23.81% 72166806447
Net profit attributable to shareholders of listed companies 1559106635311562484675 34.84% 6168310648
Net profit attributable to shareholders of listed companies after deducting non recurring profit and loss of 1451902652510105076398 and 43.68% 5388149947
Net cash flow from operating activities 3297169571827289548724 20.82% 16735501358
Jiangxi Sanxin Medtec Co.Ltd(300453) 2021 annual report summary
Basic earnings per share (yuan / share) 0.3998 0.298633.89% 0.16
Diluted earnings per share (yuan / share) 0.3950 0.291335.60% 0.15
Weighted average return on net assets 18.64%, 15.95%, 2.69%, 9.72%
(2) Quarterly main accounting data
Unit: Yuan
First quarter second quarter third quarter fourth quarter
Operating income 24614803260262845199493174768875833781864390
Net profit attributable to shareholders of listed company 3404412984371250768343331185294141027157
Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses 3052479518359604129038926344263977871291
Net cash flow from operating activities 65502599074172326621217211040412727326662
Whether the above financial indicators or their total amount are significantly different from the financial indicators related to the quarterly report and semi annual report disclosed by the company □ yes √ No 4. Share capital and shareholders (1) number of ordinary shareholders and preferred shareholders with voting rights restored and shareholding of the top 10 shareholders
Unit: shares
The annual report discloses that the voting at the end of the reporting period holds a special vote
Shareholders of 21785 preferred 0 shares whose rights have been restored at the end of the month before the ordinary day at the end of the reporting period
21886 ordinary shareholders total 0 shareholders
Total number of shareholders (if any)
number
Top 10 stocks
